Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Psilocybin/Traumatic Brain Injury (TBI)

Psilocybin for Traumatic Brain Injury (TBI)

4 papers and 1 clinical trial exploring psilocybin as a treatment for traumatic brain injury (tbi).

CompoundClassic Psychedelic

Psilocybin

Psilocybin is a naturally occurring tryptamine psychedelic that acts as a prodrug to psilocin, a potent 5-HT2A receptor agonist. It is the furthest advanced psychedelic in clinical development, with two positive Phase III trials in treatment-resistant depression and expanding regulated access in Australia, Germany, and US states.

Full Psilocybin profile
IndicationApproximately 70 million individuals worldwide sustain a TBI each year.

Traumatic Brain Injury (TBI)

Psychedelics are being investigated for their potential therapeutic effects on Traumatic Brain Injury (TBI), a condition that frequently results in various physical and psychological impairments. Early preclinical studies suggest that these compounds may influence inflammatory responses, promote neuroplasticity, and enhance neurogenesis, offering new avenues for treatment.

Full Traumatic Brain Injury (TBI) profile

Academic Research

4 papers
Open Accessindividual

Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat

In a preliminary uncontrolled study of 21 veterans with traumatic brain injury, participation in two psilocybin retreat ceremonies was associated with large reductions in PTSD, depression and anxiety symptoms and with EEG changes (reduced frontal/temporal delta–theta power and increased alpha–beta coherence) consistent with improved emotional regulation and neural communication. These findings suggest psilocybin retreats may improve psychological wellbeing and brain connectivity in veterans with TBI and warrant larger, controlled trials.

Published
August 6, 2025
Journal
Frontiers in Psychiatry
Authors
Blest-Hopley, G., Pasculli, G., Ruffell, S. G. D., Tsang, WF., Emmanuel, O., Pate, K. M., Kettner, H., Roseman, L., Erritzoe, D., Carhart-Harris, R. L.
Open Accessindividual

Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings

Veterans attending naturalistic psilocybin or ayahuasca retreats showed significant improvements across eight mental‑health and reintegration measures, with the largest reductions in depression (PHQ‑9, 29.1%) and PTSD (PCL‑5, 26.1%). Psilocybin retreats produced greater gains on most outcomes while ayahuasca yielded slightly larger PTSD improvement; those with worse baseline symptoms benefited most, with some gender-specific differences.

Published
July 7, 2025
Journal
Brain and Behavior
Authors
Calnan, M., Blest-Hopley, G., Busch, C., Adams, M., Ruffell, S. G. D., Piper, T., Roseman, L., Kettner, H., Carhart-Harris, R.
Open Accessindividual

Beliefs and Perceived Barriers Regarding Psychedelic-assisted Therapy in a Pilot Study of Service Members and Veterans With a History of Traumatic Brain Injury

In a pilot sample of 21 service members and veterans with traumatic brain injury, brief psychoeducation significantly increased positive attitudes and interest in psychedelic-assisted therapy (PAT), and most participants supported PAT availability in medical settings if proven beneficial. Participants nonetheless expressed health concerns (long-term effects, losing their mind, personality changes) and logistical barriers (time, transport, cost), indicating the need for targeted education, command support and practical facilitation to ensure access if PAT is approved.

Published
December 24, 2022
Journal
Military Medicine
Authors
Gray, J. C., Murphy, M., Carter, S. E., Johnson, M. W., Wolfgang, A. S., Ro, M. J., Maples-Keller, J. L.
Open Accessindividual

Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration

This diary study (n>100) investigates the safe and beneficial use of psychedelic microdosing (e.g. 10μg LSD) to improve positive moods by evaluating positive and negative emotional states using the PANAS checklist and written reports. The study showed that microdosers perceived improved health habits, increased energy, and improved work effectiveness. Furthermore, smaller samples demonstrated alleviation of symptoms in migraine headaches, traumatic brain injury, pre-menstrual syndromes (PMS), shingles, and other such conditions that have not been previously associated with psychedelic use.

Published
March 29, 2019
Journal
Journal of Psychoactive Drugs
Authors
Fadiman, J., Korb, S.

Clinical Trials

1 trial
RecruitingPhase I

Treatment of Persistent Post-concussive Symptoms With Psilocybin Assisted Therapy (PatACT)

This randomised, quadruple-blind, placebo-controlled trial (n=40) will evaluate the safety, feasibility, and efficacy of psilocybin-assisted therapy in adults aged 18–65 with persistent post-concussion symptoms (PPCS). Participants will receive either a high dose (25mg) or a low dose (1mg) of psilocybin and undergo 5–6 weekly sessions of BrainACT, an adapted form of Acceptance and Commitment Therapy (ACT) for individuals with acquired brain injury.

Started
October 30, 2024
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT06615908

Explore further

Search all Psilocybin papers Search all Traumatic Brain Injury (TBI) trials Full Psilocybin profile Full Traumatic Brain Injury (TBI) profile